Ipca Laboratories Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/do7rn14bdjfhqwjdwa7mhhkw.pdf

Key Takeaways


The Unichem Acquisition: Rationale, Structure & Synergies

Pranay Godha: "It was better than most of the deals that had come on our table in the last five years."

Unichem’s Current State: Assets, Utilization & Inefficiencies

Ajit Jain: "Nobody can ever guarantee what will happen in the future. There is no guarantee of what FDA can do in the future for anyone, for any site on this world."

The ₹300 Crore EBITDA Target: Drivers & Conditions

Pranay Godha: "It does include synergy benefits. Without that, this number would otherwise be a bit of a challenge."

US Market & Regulatory Overhang

Ajit Jain: "Nothing, there is status quo. So let us hope, inspection will happen soon and we are through. But as we speak, there is status quo. No development."

Integration Approach & Management Philosophy

Management: "Whatever the team, in the quality and operation side, they've generally done a good job. Their actions are speaking louder than words, I would say. So, things will more or less, be business as usual."

Unanswered Questions & Pushback

Ajit Jain: "We have talked about a lot of things which Ipca will do with their product range in terms of extending the market reach of those products. And right now, we have not made any of those kind of calculations. So right now, it's difficult to say that what would be the payback."

Guidance & Commitments

CommitmentSpecificsTimeline
Unichem revenue target~₹1,700–1,800 crores turnoverWithin two years of Ipca taking management control
Unichem EBITDA target~₹300 crores EBITDA, including synergy benefitsSecond year after Ipca takes management control
Unichem gross margin normalization60–65% on a normalized basisNo specific timeline; dependent on product mix normalization
API cost optimization programPlanned and implemented across Unichem’s API operationsApproximately one and a half years, possibly longer due to validation requirements
Deal completionCCA approval followed by open offer completionBest case approximately four months from now, dependent on CCA approval timing
GST refund unlockingSwitch from refund method to rebate method to release ~₹275 croresMaybe over a period of one year
R&D rationalization at UnichemShift to Ipca’s policy of developing products only on own APIPost-acquisition, no specific completion date

Key Metrics

MetricQ4 FY23
Acquisition stake in Unichem Laboratories33.38% for INR1,034 cr
Open offer for additional stake26% of Unichem equity, aggregating to INR806 cr presuming 100% response
Total potential investmentINR1,839.5 cr if 100% of open offer shares are available
Unichem US ANDAs filed76 ANDAs filed, 54 registered, 44 products marketed
Unichem API DMFs filed in US78 DMFs
Unichem total assets on books~INR1,400 cr
Unichem net working capital~INR950 cr
Unichem total available assets~INR2,500–2,600 cr
Unichem capacity utilization20% to 30% currently
Ipca Pithampur plant utilization~30%
Ipca Piparia plant utilization~25% to 30%
Unichem revenue guidance (2 years out)~INR1,700–1,800 cr
Unichem EBITDA guidance (2 years out)~INR300 cr, including synergy benefits
Unichem revenue growth expectation15% to 17% in next 2–3 years
Unichem US revenue contribution60%–65% of total business
Unichem top 10 products contribution70%–75% of total business
Unichem normalized gross margin expectation60% to 65%
Unichem GST refunds locked up~INR275 cr, unlockable over ~1 year
Unichem peak potential revenue from all assets~INR2,700–2,800 cr
European Commission fine on Unichem (contingent liability)INR120 cr, already considered in acquisition valuation
Deal timeline (best case)~4 months from now, subject to CCA approval